Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASKG712 in Diabetic Macular Edema
NCT05940428Phase 1Completed
- Sponsor
- Visara
- Start
- Oct 2023
- Primary completion
- Oct 2024
- Modality
- Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ASKG712 in diabetic macular edema (DME), sponsored by Visara. Primary endpoints: Incidence of ocular adverse events of the study eyes at 24 weeks and Incidence of non-ocular adverse events at 24 weeks. Started Oct 2023; status: completed.
02
Drugs
ASKG712
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT05940428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05940428.